The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory ...

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

3. Mirasol, F. AstraZeneca Invests $2.5 Billion to Establish Global Strategic R&D Center, Support Biotech Agreements, and Boost Manufacturing in China. BioPharmInternational.com, March 24, 2025. 4.

AstraZeneca has acquired all outstanding equity of EsoBiotec for a total consideration of up to $1 billion, on a cash and debt free basis. This includes an initial payment of $425 million, and up to ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON: AZN), the global biopharmaceutical company, has announced the completion of its acquisition of EsoBiotec, a biotech company specializing in cell therapies, for a ...

EsoBiotec is now a wholly owned subsidiary of AstraZeneca. AstraZeneca said the transaction will not affect its financial guidance for 2025. Shares in AstraZeneca were up 0.1% at 10,380.00 pence ...

20 May 2025 Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON: AZN), the global biopharmaceutical company, has announced the completion of its acquisition of EsoBiotec, a biotech company specializing in cell therapies, for ...

AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Conference Call April 29, ... Our proposed acquisition of EsoBiotec brings the potentially best-in-class in vivo cell therapy platform in-house, ...

EsoBiotec In March 2025, AstraZeneca entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. ... and that's clear from EsoBiotec, but other things also,” Sapra said.